Is Vascular Biogenics Ltd. overvalued or undervalued?

As of 28 March 2019, the valuation grade for Vascular Biogenics Ltd. has moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company is currently considered overvalued, especially given its P/E ratio of -0.0001 and an EV to EBITDA of 0.28, which are both concerning indicators of financial health. Additionally, the ROE stands at a staggering -170.61%, reflecting severe losses and inefficiencies.
In comparison to its peers, Vascular Biogenics Ltd. shows a stark contrast with Forte Biosciences, Inc., which has a P/E of -1.8644, and OncoCyte Corp., which is rated risky with a P/E of -3.9768. The negative returns of Vascular Biogenics Ltd. are alarming, with a year-to-date decline of 99.64% compared to a modest 2.44% gain in the S&P 500. Overall, the financial metrics and peer comparisons suggest that Vascular Biogenics Ltd. is significantly overvalued at this time.